cancer drug development
Blackstone Pays Merck $700M to Fund Development of Antibody-Drug Conjugate
Blackstone; Merck; sacituzumab tirumotecan; antibody-drug conjugate; cancer drug development; funding agreement; oncology; royalties
Actionable Insights Powered by AI
Blackstone; Merck; sacituzumab tirumotecan; antibody-drug conjugate; cancer drug development; funding agreement; oncology; royalties